A071401 (NCT02523014) **New patient registration (Step 1) to the abemaciclib cohort will close Monday, October 3, 2022, at 3:30 PM CST.**

Study Number: A071401 (NCT02523014) **New patient registration (Step 1) to the abemaciclib cohort will close Monday, October 3, 2022, at 3:30 PM CST.**

This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningioma that is growing, spreading, or getting worse. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Please Note:

Protocol must have open slot available for registration. See protocol for all details, amendment #6. Cohorts NF2Grande I and NF2 Grade II/III are closed.

Contact Person(s)

• MBMC, Henry Robinson, 314-996-5865

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.